By Dr. Yahia Anane

Statins are among the most prescribed drugs in the world. They block HMG-CoA reductase — the rate-limiting enzyme of the mevalonate pathway. And cancer cells depend on this same pathway to fuel membrane synthesis, isoprenoid production, and downstream oncogenic signaling.

The mechanistic case for statins in cancer is genuinely strong. The problem is everything statins do besides that.

How Statins Work Against Cancer

• Induce apoptosis through mitochondrial pathways, disrupting the survival balance tumor cells depend on
• Suppress Ras and RhoA — key oncogenic proteins that rely on mevalonate-derived isoprenoids for membrane attachment and activity
• Reduce angiogenesis through HIF-1α suppression, limiting the vascular infrastructure tumors need to expand
• Restore CD8+ T-cell activity by lowering PD-1 expression, partially reversing immune exhaustion in the tumor microenvironment
• Sensitize resistant cancer cells to chemotherapy, improving response in some treatment-resistant populations

This is not fringe theory — these mechanisms are documented and mechanistically coherent with how the mevalonate pathway supports tumor growth.

The Dark Side

1 — CoQ10 depletion. Statins block the same enzyme that produces CoQ10, the mitochondria’s primary electron-transport cofactor. Cancer patients already operate with compromised mitochondrial function — depleting CoQ10 further undermines the cellular energy production that healthy tissue needs to tolerate treatment and maintain resilience.

2 — Raised blood glucose and diabetes risk. Statins are associated with new-onset diabetes through beta-cell dysfunction. Blood glucose is cancer’s primary fuel source through Warburg-driven glycolysis. A drug that suppresses one oncogenic pathway while elevating the fuel for another is working against itself.

3 — Muscle damage and liver stress. Statin-related muscle symptoms affect 5–20% of patients. Cancer patients already face cachexia — progressive muscle wasting driven by inflammatory cytokines like IL-6 and TNF-α. Adding a drug with known myopathic and hepatotoxic potential compounds a problem that is already working against survival.

4 — Cholesterol lowering in the wrong context. Cholesterol is the precursor for steroid hormone production, vitamin D synthesis, and cell membrane integrity — all of which matter directly to immune function and hormonal stability. Aggressively suppressing cholesterol in a metabolically compromised cancer patient creates downstream instability rather than benefit.

Bottom Line

Statins have real anti-cancer mechanisms — the science behind mevalonate pathway inhibition is legitimate. But CoQ10 depletion, elevated glucose, muscle and liver burden, and disrupted hormone synthesis make them very difficult to justify in a cancer patient who is already metabolically compromised.

The mevalonate and downstream growth pathways can be targeted more cleanly through other agents — berberine and metformin hit IGF-1/PI3K-AKT-mTOR signaling and glucose metabolism without the mitochondrial cost; itraconazole disrupts intracellular cholesterol trafficking and mTOR activation through a different mechanism entirely, without statins’ systemic side-effect profile.

Same general territory. Fewer self-inflicted wounds.

This is why statins will never be part of my protocol.

Dr. Yahia Anane — Metabolic Cancer Researcher | drananeyahia.com